International HIV/Viral Hepatitis Co-Infection Satellite Meeting

News | Published on 18 Jul 2014

International HIV/Viral Hepatitis Co-Infection Satellite Meeting

Friday 18 - Saturday 19 July 2014
Intercontinental Melbourne the Rialto
Melbourne, Australia

Registration is open on the meeting website

Theme: HIV / Viral hepatitis: antiviral therapy development and implementation

The recent development of highly effective antiviral therapy for HBV and HCV provides the opportunity to counter the rising burden of chronic liver disease among people living with HIV. Global antiretroviral therapy scale-up should limit HBV-related liver disease, through dual antiviral activity. Furthermore, development of antiretroviral therapy delivery infrastructure should enhance implementation of interferon-free direct acting antiviral (DAA) regimens for HCV once available. However, several barriers to access and impact of new HCV therapies exist including low levels of HCV screening, limited liver disease staging, and lack of HCV-specific education and training of HIV health care professionals. The focus of the meeting will be development of strategies to enhance implementation of viral hepatitis antiviral therapy, particularly in preparation for the highly effective interferon-free DAA regimens for chronic HCV.

The International HIV/Viral Hepatitis Co-Infection Satellite Meeting is a pre-conference meeting and an independent affiliated event to the International AIDS Conference which is being held in Australia for the first time in 2014. The Meeting is being run by ASHM and supported by the Kirby Institute and the European AIDS Clinical Society (EACS). Logistics for the meeting are being managed by the ASHM Conference & Events Division.
    
Program outline:
Friday: Full-day Meeting Program and Evening Welcome Drinks
Saturday: Full-day Meeting Program
For the full program and to register, visit the meeting website.